Angiotensin Receptor Blocker Helps Improve Outcomes for Non-obese COVID-19 Patients, Study Shows

According to a study that the usage of angiotensin receptor blocker or ARB candesartan seems to confer benefits for length of hospital stay, radiological outcome, and time-to-negative swab in the subgroup of non-obese patients with COVID-19.

Photo: ACE Inhibitor Medication | InStyleHealth


Research was conducted in the early months of COVID-19 pandemic and involved 75 ARB-naïve patients with COVID-19, none of whom received intensive care unit (ICU) care. There was a total of 35 patients who received candesartan (average age of 41 years old, with mean BMI 23.35 kg/m2), of whom 9.3% were hypertensive, 5.3% were diabetic, 12% were current smokers, and 89.33% were clinical mild-moderate cases while 10.67% were severe cases.

Candesartan was administered at 4 mg to 32 mg once daily, titrated according to blood pressure tolerance. Treatment was postponed if the patient’s systolic blood pressure or SBP fell below 90 mm Hg and restarted when the SBP was above 100 mm Hg.

All the patients received the control treatment regimen comprising azithromycin 500 mg once daily or levofloxacin IV 750 mg once daily, hydrochloroquine 400 mg once daily, and intravenous vitamin C 1,000 mg, along with symptomatic medications and additional antibiotics based on physician’s discretion.

Comparing with the control group, the candesartan group had a markedly shorter hospital stay with no increased risk of intensive care.

For the subgroup of non-obese patients, a negative swab occurred sooner among patients who received candesartan vs control treatment only, as was improvement in chest X-ray.

 

Source: Int J Infect Dis 2021;doi:10.1016/j.ijid.2021.05.019

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post